1Ishimura M, Ohga S, Nomura A, et al. Successful umbilical lord blood transplantation for severe chronic active Epstein-Barr virus infection after the double failure of hematopoietic stem cell transplantation [J]. Am J Hematol,2005,80:207-212.
2Kimura H, Hoshino Y, kanegane H,et al. Clinical and virologic characteristics of chronic active Epstein-Barrvirus infection[J]. Blood,2001,98(2) :280-286.
3Kimura H, Hoshino Y, Hara S,et al. Differences bet-ween T cell- type and natural killer cell-type chronicactive Epstein-Barr virus infection[J]. J Infect Dis, 2005,191 (4) :531 -539.
4Roh E J,Chung EH,Chang YP. A case of hypersensitivity to mosquito bite associated with Epstein-barr viral infection and natural killer cell lymphocytosis[J].Journal of Korean Medical Science,2010.321-323.
5Cocks BG,de Waal Malefyt R,Galizzi JP. IL-13 induces proliferation and differentiation of human B cells activated by the CD40 tigand[J].International Immunology,1993.657-663.doi:10.1093/intimm/5.6.657.
6Tsai SC,Lin SJ,Chen PW. EBV Zta protein induces the expression of interleukin-13,promoting the proliferation of EBVinfected B cells and lymphoblastoid cell lines[J].Blood,2009.109-118.
7Campo E,Swerdlow SH,Harris NL. The 2008 WHO classification of lymphoid neoplasms and beyond:evolving concepts and practical applications[J].Blood,2011.5019-5032.doi:10.1182/blood-2011-01-293050.
8Ohshima K,Kimura H,Yoshino T. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults:overlap with chronic active EBV infection and infantile fulminant EBV T-LPD[J].Pathology International,2008,(4):209-217.doi:10.1111/j.1440-1827.2008.02213.x.
9Cohen JI,Kimura H,Nakamura S. Epstein-Barr virusassociated lymphoproliferative disease in non-immunocompromised hosts:a status report and summary of an international meeting,8-9 September 2008[J].Annals of Oncology,2009.1472-1482.
